Indian Immunologicals Limited Sets Up a New Rs. 250 Crore Facility in Hyderabad
The IIL has developed this facility considering the growing demand for the next 10 years for human vaccines and animal health formulations.
The IIL has developed this facility considering the growing demand for the next 10 years for human vaccines and animal health formulations.
‘IIL has inaugurated a new bovine serum manufacturing facility in New Zealand. With this new facility IIL not only becomes self sufficient for a key ingredient, but will also have spare capacity to provide it to other quality conscious manufacturers.’
Tweet it Now
IIL established PBL in 2014 to gain control over the supplies of a key ingredient used in vaccine manufacture. Serum from New Zealand is highly regarded as the country is free from several diseases listed by the World Organization for Animal Health (OIE). This new plant can manufacture up to 300 tonne of serum. Balasubramaniam said, "Pristine would bring the science of biopharmaceuticals to the users of bovine serum and the rigor in quality assurance and management which will in turn ensure that users bring high quality to their products."
IIL's deputy managing director Anand Kumar said, "With this new facility IIL not only becomes self sufficient for a key ingredient but also has spare capacity to provide it to other quality conscious manufacturers as well."
Sanofi's Snakebite Serum Shortage Could Lead to Unnecessary Deaths: MSF
Fav-Afrique could no longer compete with cheaper alternatives flooding the market from Asia, Latin America and Africa.
Fav-Afrique could no longer compete with cheaper alternatives flooding the market from Asia, Latin America and Africa.
India's Serum Institute Seeks Government Approval To Launch Dengue Drug
Serum Institute bought rights from US biotech Visterra to sell, VIS513 as a treatment for dengue, which is priced between Rs 5,000 and Rs 10,000 per injection.
Serum Institute bought rights from US biotech Visterra to sell, VIS513 as a treatment for dengue, which is priced between Rs 5,000 and Rs 10,000 per injection.
Godrej Ventures Into Vaccine Protection Sector With Sure Chill - a Britain-based Company
The company has patented the use of refrigeration that does not need constant power to refrigerate. It guarantees maintenance at a temperature of 4 degrees Celsius.
The company has patented the use of refrigeration that does not need constant power to refrigerate. It guarantees maintenance at a temperature of 4 degrees Celsius.
